AEOL 11216

AEOL 11216 is a synthetic metalloporphyrin compound developed by Aeolus Pharmaceuticals as a catalytic antioxidant. It functions as a small molecule mimic of endogenous antioxidant enzymes, specifically superoxide dismutase (SOD) and catalase, which allows it to scavenge reactive oxygen species (ROS) and mitigate oxidative stress. Preclinical studies have demonstrated that AEOL 11216 possesses blood-brain barrier permeability when administered systemically, making it a viable candidate for the treatment of neurodegenerative disorders. Its primary development focus has been as a neuroprotective agent for Parkinson's disease, targeting the oxidative damage that contributes to neuronal loss.